Haemonetics 3rd Quarter Fiscal Year 2022 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Haemonetics (HAE) Tops Q3 EPS by 11c
February 8, 2022 6:07 AM ESTHaemonetics (NYSE: HAE) reported Q3 EPS of $0.84, $0.11 better than the analyst estimate of $0.73. Revenue for the quarter came in at $260 million versus the consensus estimate of $266.94 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.45-$2.55, versus the consensus of $2.53.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
... More